Top

Published in:

Open Access 13-01-2024 | Insulins | Article

Skeletal muscle TET3 promotes insulin resistance through destabilisation of PGC-1α

Authors: Beibei Liu, Di Xie, Xinmei Huang, Sungho Jin, Yangyang Dai, Xiaoli Sun, Da Li, Anton M. Bennett, Sabrina Diano, Yingqun Huang

Published in: Diabetologia | Issue 4/2024

Abstract

Aim/hypothesis

The peroxisome proliferator-activated receptor-γ coactivator α (PGC-1α) plays a critical role in the maintenance of glucose, lipid and energy homeostasis by orchestrating metabolic programs in multiple tissues in response to environmental cues. In skeletal muscles, PGC-1α dysregulation has been associated with insulin resistance and type 2 diabetes but the underlying mechanisms have remained elusive. This research aims to understand the role of TET3, a member of the ten-eleven translocation (TET) family dioxygenases, in PGC-1α dysregulation in skeletal muscles in obesity and diabetes.

Methods

TET expression levels in skeletal muscles were analysed in humans with or without type 2 diabetes, as well as in mouse models of high-fat diet (HFD)-induced or genetically induced (ob/ob) obesity/diabetes. Muscle-specific Tet3 knockout (mKD) mice were generated to study TET3’s role in muscle insulin sensitivity. Genome-wide expression profiling (RNA-seq) of muscle tissues from wild-type (WT) and mKD mice was performed to mine deeper insights into TET3-mediated regulation of muscle insulin sensitivity. The correlation between PGC-1α and TET3 expression levels was investigated using muscle tissues and in vitro-derived myotubes. PGC-1α phosphorylation and degradation were analysed using in vitro assays.

Results

TET3 expression was elevated in skeletal muscles of humans with type 2 diabetes and in HFD-fed and ob/ob mice compared with healthy controls. mKD mice exhibited enhanced glucose tolerance, insulin sensitivity and resilience to HFD-induced insulin resistance. Pathway analysis of RNA-seq identified ‘Mitochondrial Function’ and ‘PPARα Pathway’ to be among the top biological processes regulated by TET3. We observed higher PGC-1α levels (~25%) in muscles of mKD mice vs WT mice, and lower PGC-1α protein levels (~25–60%) in HFD-fed or ob/ob mice compared with their control counterparts. In human and murine myotubes, increased PGC-1α levels following TET3 knockdown contributed to improved mitochondrial respiration and insulin sensitivity. TET3 formed a complex with PGC-1α and interfered with its phosphorylation, leading to its destabilisation.

Conclusions/interpretation

Our results demonstrate an essential role for TET3 in the regulation of skeletal muscle insulin sensitivity and suggest that TET3 may be used as a potential therapeutic target for the metabolic syndrome.

Data availability

Sequences are available from the Gene Expression Omnibus (https://www.ncbi.nlm.nih.gov/geo/) with accession number of GSE224042.

Graphical Abstract

Available only for authorised users

DeFronzo RA, Ferrannini E, Groop L et al (2015) Type 2 diabetes mellitus. Nat Rev Dis Primers 1:15019. https://doi.org/10.1038/nrdp.2015.19CrossRefPubMed

Bluher M (2019) Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol 15(5):288–298. https://doi.org/10.1038/s41574-019-0176-8CrossRefPubMed

Martin BC, Warram JH, Krolewski AS, Bergman RN, Soeldner JS, Kahn CR (1992) Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet 340(8825):925–929. https://doi.org/10.1016/0140-6736(92)92814-vCrossRefPubMed

Rothman DL, Magnusson I, Cline G et al (1995) Decreased muscle glucose transport/phosphorylation is an early defect in the pathogenesis of non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci U S A 92(4):983–987. https://doi.org/10.1073/pnas.92.4.983CrossRefPubMedPubMedCentralADS

Petersen MC, Shulman GI (2018) Mechanisms of insulin action and insulin resistance. Physiol Rev 98(4):2133–2223. https://doi.org/10.1152/physrev.00063.2017CrossRefPubMedPubMedCentral

Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM (1998) A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92(6):829–839. https://doi.org/10.1016/s0092-8674(00)81410-5CrossRefPubMed

Lin J, Handschin C, Spiegelman BM (2005) Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab 1(6):361–370. https://doi.org/10.1016/j.cmet.2005.05.004CrossRefPubMed

Chan MC, Arany Z (2014) The many roles of PGC-1alpha in muscle–recent developments. Metabolism 63(4):441–451. https://doi.org/10.1016/j.metabol.2014.01.006CrossRefPubMedPubMedCentral

Lukaszuk B, Kurek K, Miklosz A, Zendzian-Piotrowska M, Chabowski A (2015) The role of PGC-1alpha in the development of insulin resistance in skeletal muscle - revisited. Cell Physiol Biochem 37(6):2288–2296. https://doi.org/10.1159/000438584CrossRefPubMed

10.

Benton CR, Wright DC, Bonen A (2008) PGC-1alpha-mediated regulation of gene expression and metabolism: implications for nutrition and exercise prescriptions. Appl Physiol Nutr Metab 33(5):843–862. https://doi.org/10.1139/H08-074CrossRefPubMed

11.

Miura S, Kai Y, Ono M, Ezaki O (2003) Overexpression of peroxisome proliferator-activated receptor gamma coactivator-1alpha down-regulates GLUT4 mRNA in skeletal muscles. J Biol Chem 278(33):31385–31390. https://doi.org/10.1074/jbc.M304312200CrossRefPubMed

12.

Choi CS, Befroy DE, Codella R et al (2008) Paradoxical effects of increased expression of PGC-1alpha on muscle mitochondrial function and insulin-stimulated muscle glucose metabolism. Proc Natl Acad Sci U S A 105(50):19926–19931. https://doi.org/10.1073/pnas.0810339105CrossRefPubMedPubMedCentralADS

13.

Benton CR, Nickerson JG, Lally J et al (2008) Modest PGC-1alpha overexpression in muscle in vivo is sufficient to increase insulin sensitivity and palmitate oxidation in subsarcolemmal, not intermyofibrillar, mitochondria. J Biol Chem 283(7):4228–4240. https://doi.org/10.1074/jbc.M704332200CrossRefPubMed

14.

Mathai AS, Bonen A, Benton CR, Robinson DL, Graham TE (2008) Rapid exercise-induced changes in PGC-1alpha mRNA and protein in human skeletal muscle. J Appl Physiol (1985) 105(4):1098–1105. https://doi.org/10.1152/japplphysiol.00847.2007CrossRefPubMed

15.

Benton CR, Holloway GP, Han XX et al (2010) Increased levels of peroxisome proliferator-activated receptor gamma, coactivator 1 alpha (PGC-1alpha) improve lipid utilisation, insulin signalling and glucose transport in skeletal muscle of lean and insulin-resistant obese Zucker rats. Diabetologia 53(9):2008–2019. https://doi.org/10.1007/s00125-010-1773-1CrossRefPubMed

16.

Patti ME, Butte AJ, Crunkhorn S et al (2003) Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc Natl Acad Sci U S A 100(14):8466–8471. https://doi.org/10.1073/pnas.1032913100CrossRefPubMedPubMedCentralADS

17.

Cheng Z, Tseng Y, White MF (2010) Insulin signaling meets mitochondria in metabolism. Trends Endocrinol Metab 21(10):589–598. https://doi.org/10.1016/j.tem.2010.06.005CrossRefPubMedPubMedCentral

18.

Mootha VK, Lindgren CM, Eriksson KF et al (2003) PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34(3):267–273. https://doi.org/10.1038/ng1180CrossRefPubMed

19.

Szendroedi J, Phielix E, Roden M (2011) The role of mitochondria in insulin resistance and type 2 diabetes mellitus. Nat Rev Endocrinol 8(2):92–103. https://doi.org/10.1038/nrendo.2011.138CrossRefPubMed

20.

Wu X, Zhang Y (2017) TET-mediated active DNA demethylation: mechanism, function and beyond. Nat Rev Genet 18(9):517–534. https://doi.org/10.1038/nrg.2017.33CrossRefPubMed

21.

Lio CJ, Yue X, Lopez-Moyado IF, Tahiliani M, Aravind L, Rao A (2020) TET methylcytosine oxidases: new insights from a decade of research. J Biosci 45:21. https://doi.org/10.1007/s12038-019-9973-4CrossRefPubMedPubMedCentral

22.

Chen Q, Chen Y, Bian C, Fujiki R, Yu X (2013) TET2 promotes histone O-GlcNAcylation during gene transcription. Nature 493(7433):561–564. https://doi.org/10.1038/nature11742CrossRefPubMedADS

23.

Vella P, Scelfo A, Jammula S et al (2013) Tet proteins connect the O-linked N-acetylglucosamine transferase Ogt to chromatin in embryonic stem cells. Mol Cell 49(4):645–656. https://doi.org/10.1016/j.molcel.2012.12.019CrossRefPubMed

24.

Zhang Q, Zhao K, Shen Q et al (2015) Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6. Nature 525(7569):389–393. https://doi.org/10.1038/nature15252CrossRefPubMedPubMedCentralADS

25.

Xue S, Liu C, Sun X et al (2016) TET3 inhibits type I IFN production independent of DNA demethylation. Cell Rep 16(4):1096–1105. https://doi.org/10.1016/j.celrep.2016.06.068CrossRefPubMed

26.

Guan W, Guyot R, Samarut J, Flamant F, Wong J, Gauthier KC (2017) Methylcytosine dioxygenase TET3 interacts with thyroid hormone nuclear receptors and stabilizes their association to chromatin. Proc Natl Acad Sci U S A 114(31):8229–8234. https://doi.org/10.1073/pnas.1702192114CrossRefPubMedPubMedCentralADS

27.

Damal Villivalam S, You D, Kim J et al (2020) TET1 is a beige adipocyte-selective epigenetic suppressor of thermogenesis. Nat Commun 11(1):4313. https://doi.org/10.1038/s41467-020-18054-yCrossRefPubMedPubMedCentralADS

28.

Byun S, Lee CH, Jeong H et al (2022) Loss of adipose TET proteins enhances beta-adrenergic responses and protects against obesity by epigenetic regulation of beta3-AR expression. Proc Natl Acad Sci U S A 119(26):e2205626119. https://doi.org/10.1073/pnas.2205626119CrossRefPubMedPubMedCentral

29.

Pan W, Zhu S, Qu K et al (2017) The DNA methylcytosine dioxygenase Tet2 sustains immunosuppressive function of tumor-infiltrating myeloid cells to promote melanoma progression. Immunity 47(2):284-297 e285. https://doi.org/10.1016/j.immuni.2017.07.020CrossRefPubMedPubMedCentral

30.

Montalban-Loro R, Lozano-Urena A, Ito M et al (2019) TET3 prevents terminal differentiation of adult NSCs by a non-catalytic action at Snrpn. Nat Commun 10(1):1726. https://doi.org/10.1038/s41467-019-09665-1CrossRefPubMedPubMedCentralADS

31.

Tanaka S, Ise W, Inoue T et al (2020) Tet2 and Tet3 in B cells are required to repress CD86 and prevent autoimmunity. Nat Immunol 21(8):950–961. https://doi.org/10.1038/s41590-020-0700-yCrossRefPubMed

32.

Wang H, Huang Y, Yu M et al (2021) Muscle regeneration controlled by a designated DNA dioxygenase. Cell Death Dis 12(6):535. https://doi.org/10.1038/s41419-021-03817-2CrossRefPubMedPubMedCentral

33.

Zhang H, Wang S, Zhou Q et al (2022) Disturbance of calcium homeostasis and myogenesis caused by TET2 deletion in muscle stem cells. Cell Death Discov 8(1):236. https://doi.org/10.1038/s41420-022-01041-1CrossRefPubMedPubMedCentral

34.

Li D, Cao T, Sun X et al (2020) Hepatic TET3 contributes to type-2 diabetes by inducing the HNF4a fetal isoform. Nat Commun 11(1):342. https://doi.org/10.1038/s41467-019-14185-zCrossRefPubMedPubMedCentralADS

35.

Xie D, Chen F, Zhang Y et al (2022) Let-7 underlies metformin-induced inhibition of hepatic glucose production. Proc Natl Acad Sci U S A 119(14):e2122217119. https://doi.org/10.1073/pnas.2122217119CrossRefPubMedPubMedCentral

36.

Xie D, Stutz B, Li F et al (2022) TET3 epigenetically controls feeding and stress response behaviors via AGRP neurons. J Clin Invest 132(19):e162365. https://doi.org/10.1172/JCI162365CrossRefPubMedPubMedCentral

37.

Pihlajamaki J, Lerin C, Itkonen P et al (2011) Expression of the splicing factor gene SFRS10 is reduced in human obesity and contributes to enhanced lipogenesis. Cell Metab 14(2):208–218. https://doi.org/10.1016/j.cmet.2011.06.007CrossRefPubMedPubMedCentral

38.

Jin W, Goldfine AB, Boes T et al (2011) Increased SRF transcriptional activity in human and mouse skeletal muscle is a signature of insulin resistance. J Clin Invest 121(3):918–929. https://doi.org/10.1172/JCI41940CrossRefPubMedPubMedCentral

39.

Varemo L, Henriksen TI, Scheele C et al (2017) Type 2 diabetes and obesity induce similar transcriptional reprogramming in human myocytes. Genome Med 9(1):47. https://doi.org/10.1186/s13073-017-0432-2CrossRefPubMedPubMedCentral

40.

Song J, Lv H, Liu B et al (2023) Let-7 suppresses liver fibrosis by inhibiting hepatocyte apoptosis and TGF-beta production. Mol Metab 78:101828. https://doi.org/10.1016/j.molmet.2023.101828CrossRefPubMedPubMedCentral

41.

Lv H, Catarino J, Li D et al (2023) A small-molecule degrader of TET3 as treatment for anorexia nervosa in an animal model. Proc Natl Acad Sci U S A 120(16):e2300015120. https://doi.org/10.1073/pnas.2300015120CrossRefPubMedPubMedCentral

42.

Miniou P, Tiziano D, Frugier T, Roblot N, Le Meur M, Melki J (1999) Gene targeting restricted to mouse striated muscle lineage. Nucleic Acids Res 27(19):e27. https://doi.org/10.1093/nar/27.19.e27CrossRefPubMedPubMedCentral

43.

Wang G, Yu Y, Cai W et al (2020) Muscle-specific insulin receptor overexpression protects mice from diet-induced glucose intolerance but leads to postreceptor insulin resistance. Diabetes 69(11):2294–2309. https://doi.org/10.2337/db20-0439CrossRefPubMedPubMedCentral

44.

Long YC, Cheng Z, Copps KD, White MF (2011) Insulin receptor substrates Irs1 and Irs2 coordinate skeletal muscle growth and metabolism via the Akt and AMPK pathways. Mol Cell Biol 31(3):430–441. https://doi.org/10.1128/MCB.00983-10CrossRefPubMed

45.

Fernandez-Marcos PJ, Auwerx J (2011) Regulation of PGC-1alpha, a nodal regulator of mitochondrial biogenesis. Am J Clin Nutr 93(4):884S – 890. https://doi.org/10.3945/ajcn.110.001917CrossRefPubMedPubMedCentral

46.

Luo X, Liao C, Quan J et al (2019) Posttranslational regulation of PGC-1alpha and its implication in cancer metabolism. Int J Cancer 145(6):1475–1483. https://doi.org/10.1002/ijc.32253CrossRefPubMedPubMedCentral

47.

Ruan HB, Han X, Li MD et al (2012) O-GlcNAc transferase/host cell factor C1 complex regulates gluconeogenesis by modulating PGC-1alpha stability. Cell Metab 16(2):226–237. https://doi.org/10.1016/j.cmet.2012.07.006CrossRefPubMedPubMedCentral

48.

Genders AJ, Holloway GP, Bishop DJ (2020) Are alterations in skeletal muscle mitochondria a cause or consequence of insulin resistance? Int J Mol Sci 21(18):6948. https://doi.org/10.3390/ijms21186948CrossRefPubMedPubMedCentral

49.

Olson BL, Hock MB, Ekholm-Reed S et al (2008) SCFCdc4 acts antagonistically to the PGC-1alpha transcriptional coactivator by targeting it for ubiquitin-mediated proteolysis. Genes Dev 22(2):252–264. https://doi.org/10.1101/gad.1624208CrossRefPubMedPubMedCentral

50.

Trausch-Azar J, Leone TC, Kelly DP, Schwartz AL (2010) Ubiquitin proteasome-dependent degradation of the transcriptional coactivator PGC-1{alpha} via the N-terminal pathway. J Biol Chem 285(51):40192–40200. https://doi.org/10.1074/jbc.M110.131615CrossRefPubMedPubMedCentral

51.

Puigserver P, Rhee J, Lin J et al (2001) Cytokine stimulation of energy expenditure through p38 MAP kinase activation of PPARgamma coactivator-1. Mol Cell 8(5):971–982. https://doi.org/10.1016/s1097-2765(01)00390-2CrossRefPubMed

52.

Fan M, Rhee J, St-Pierre J et al (2004) Suppression of mitochondrial respiration through recruitment of p160 myb binding protein to PGC-1alpha: modulation by p38 MAPK. Genes Dev 18(3):278–289. https://doi.org/10.1101/gad.1152204CrossRefPubMedPubMedCentral

53.

Roth RJ, Le AM, Zhang L et al (2009) MAPK phosphatase-1 facilitates the loss of oxidative myofibers associated with obesity in mice. J Clin Invest 119(12):3817–3829. https://doi.org/10.1172/JCI39054CrossRefPubMedPubMedCentral

54.

Cao T, Jiang Y, Wang Z et al (2019) H19 lncRNA identified as a master regulator of genes that drive uterine leiomyomas. Oncogene 38(27):5356–5366. https://doi.org/10.1038/s41388-019-0808-4CrossRefPubMedPubMedCentral

55.

Xu Y, Sun X, Zhang R et al (2020) A positive feedback loop of TET3 and TGF-beta1 promotes liver fibrosis. Cell Rep 30(5):1310-1318 e1315. https://doi.org/10.1016/j.celrep.2019.12.092CrossRefPubMedPubMedCentral

56.

Gerecke C, Egea Rodrigues C, Homann T, Kleuser B (2022) The role of ten-eleven translocation proteins in inflammation. Front Immunol 13:861351. https://doi.org/10.3389/fimmu.2022.861351CrossRefPubMedPubMedCentral

57.

Rui J, Deng S, Perdigoto AL et al (2021) Tet2 controls the responses of beta cells to inflammation in autoimmune diabetes. Nat Commun 12(1):5074. https://doi.org/10.1038/s41467-021-25367-zCrossRefPubMedPubMedCentralADS

58.

Eschbach J, Schwalenstocker B, Soyal SM et al (2013) PGC-1alpha is a male-specific disease modifier of human and experimental amyotrophic lateral sclerosis. Hum Mol Genet 22(17):3477–3484. https://doi.org/10.1093/hmg/ddt202CrossRefPubMed

59.

Weydt P, Pineda VV, Torrence AE et al (2006) Thermoregulatory and metabolic defects in Huntington’s disease transgenic mice implicate PGC-1alpha in Huntington’s disease neurodegeneration. Cell Metab 4(5):349–362. https://doi.org/10.1016/j.cmet.2006.10.004CrossRefPubMed

60.

Arany Z, He H, Lin J et al (2005) Transcriptional coactivator PGC-1 alpha controls the energy state and contractile function of cardiac muscle. Cell Metab 1(4):259–271. https://doi.org/10.1016/j.cmet.2005.03.002CrossRefPubMed

61.

Lin J, Wu PH, Tarr PT et al (2004) Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice. Cell 119(1):121–135. https://doi.org/10.1016/j.cell.2004.09.013CrossRefPubMed

62.

Handschin C, Kobayashi YM, Chin S, Seale P, Campbell KP, Spiegelman BM (2007) PGC-1alpha regulates the neuromuscular junction program and ameliorates Duchenne muscular dystrophy. Genes Dev 21(7):770–783. https://doi.org/10.1101/gad.1525107CrossRefPubMedPubMedCentral

63.

Arany Z (2008) PGC-1 coactivators and skeletal muscle adaptations in health and disease. Curr Opin Genet Dev 18(5):426–434. https://doi.org/10.1016/j.gde.2008.07.018CrossRefPubMedPubMedCentral

Title: Skeletal muscle TET3 promotes insulin resistance through destabilisation of PGC-1α
Authors: Beibei Liu
Di Xie
Xinmei Huang
Sungho Jin
Yangyang Dai
Xiaoli Sun
Da Li
Anton M. Bennett
Sabrina Diano
Yingqun Huang
Publication date: 13-01-2024
Publisher: Springer Berlin Heidelberg
Keywords: Insulins
Insulins
Obesity
Obesity
Published in: Diabetologia / Issue 4/2024
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-023-06073-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Aim/hypothesis

Methods

Results

Conclusions/interpretation

Data availability

Graphical Abstract

Please log in to get access to this content

Other articles of this Issue 4/2024

A novel subpopulation of monocytes with a strong interferon signature indicated by SIGLEC-1 is present in patients with in recent-onset type 1 diabetes

Canagliflozin regulates metabolic reprogramming in diabetic kidney disease by inducing fasting-like and aestivation-like metabolic patterns

Cost–utility analysis of Dexcom G6 real-time continuous glucose monitoring versus FreeStyle Libre 1 intermittently scanned continuous glucose monitoring in adults with type 1 diabetes in Belgium

Remission of type 2 diabetes

Morning exercise as fasted-state activity

Progression of type 1 diabetes is associated with high levels of soluble PD-1 in islet autoantibody-positive children

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials